EIP Pharma
11 Channing Street
Cambridge
Massachusetts
02138-4713
United States
Tel: 617-868-0510
Email: jalam@eippharma.com
About EIP Pharma
EIP Pharma, LLC is a private company that has licensed-in and is developing VX-745, a phase 2 clinical-stage oral investigational drug that targets neuro-inflammation, dysfunction of microglia (the major immune-cell in the brain) and the effects of inflammation in the brain on neuronal & synaptic function.YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CEO: John Alam
Founder: Sylvie Grégoire
CLINICAL TRIAL:
Please click here for clinical trial information.
36 articles about EIP Pharma
-
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
8/14/2023
EIP Pharma Inc. today announced that the first patient has been dosed in the Company's RewinD-LB Phase 2b clinical trial of neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB).
-
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference
8/3/2023
EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, announced that the Company's senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET.
-
EIP Pharma to Present at JMP Securities Life Sciences Conference 2023
5/11/2023
EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, announced that the Company's senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET.
-
EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023
4/3/2023
EIP Pharma Inc. announced the oral presentation by academic investigators from the Amsterdam University Medical Center of neuroimaging results from a phase 2a clinical study in patients with early Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases 2023, which took place virtually and in person March 28 – April 1, 2023, in Gothenburg, Sweden.
-
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
3/30/2023
EIP Pharma Inc. and Diffusion Pharmaceuticals Inc., announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies.
-
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies
1/18/2023
EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in individuals with dementia with Lewy bodies (DLB).
-
Presentation of MRI data at Clinical Trials and Alzheimer's Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer's disease (AD)
12/2/2022
EIP Pharma Inc. today announced that a presentation at the 15th Annual Clinical Trials in Alzheimer's disease (CTAD) meeting in San Francisco demonstrates that neflamapimod may reverse pathologic disease progression in the basal forebrain cholinergic system in the early stages of Alzheimer's disease.
-
EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications
9/21/2022
EIP Pharma Inc. announced publication of an article in Nature Communications showing translational results from preclinical animal models to an exploratory, placebo-controlled clinical trial of neflamapimod in patients with mild to moderate Dementia with Lewy Bodies.
-
EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies
11/10/2021
EIP Pharma Inc., announces that the final results of the AscenD-LB phase 2 clinical study of their oral investigational drug, neflamapimod, in mild-to-moderate dementia with Lewy bodies were presented today at the 14th Clinical Trials in Alzheimer's Disease (CTAD) meeting.
-
EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment
11/4/2021
EIP Pharma Inc. data will be presented at the 14th Clinical Trials in Alzheimer's Disease (CTAD) meeting that will be held in Boston November 9th through 12th, 2021.
-
EIP Pharma appoints Dr. Marwan Sabbagh to Board of Directors
11/4/2021
EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors with immediate effect.
-
EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke
12/16/2020
Administration of neflamapimod during the subacute phase after transient ischemia induced stroke in rats promoted functional recovery Associated increased levels of brain-derived neurotrophic factor (BDNF) suggest the effects were mediated by increasing synaptic plasticity
-
EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
11/7/2020
Results of AscenD-LB Phase 2 clinical study demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB)
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)
10/6/2020
EIP Pharma, Inc., a CNS-focused therapeutics company, announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery.
-
EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting
12/5/2019
EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands.
-
Clinical Catch-Up: November 4-8
11/11/2019
It was a busy week for clinical trial updates for the first week of November. Here’s a look. -
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
11/7/2019
Phase 2 clinical trial of neflamapimod in patients with mild-to-moderate DLB currently enrolling patients in the U.S. and the Netherlands
-
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
11/7/2019
EIP Pharma, Inc., a CNS-focused therapeutics company, announced that the REVERSE-SD study of neflamapimod in early-stage Alzheimer's disease met its secondary objectives of target engagement and proof-of-mechanism demonstrating statistically significant reductions relative to placebo in cerebrospinal fluid levels of phospho-tau and tau, the major markers of neurodegeneration and axonal damage.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.